Januvia licence extension

The licence for Januvia (sitagliptin) has been extended to include two additional uses in patients with type II diabetes.

Januvia is now indicated to improve glycaemic control in combination with a sulfonylurea when diet and exercise plus maximal tolerated dose of a sulfonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindication or intolerance.

It is also indicated for triple therapy in combination with a sulfonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.

View Januvia drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Prescribers alerted to topical steroid withdrawal reactions

Prescribers alerted to topical steroid withdrawal reactions

The MHRA has issued advice for prescribers to minimise...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Long-term antipsychotic use linked to breast cancer

Long-term antipsychotic use linked to breast cancer

Recent research indicates a significant increase in...